AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials.
The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago, combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA).
AstraZeneca plans to file PT003 for approval commencing in 2015.
Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca's drug is administered with a pressurized meter-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.